SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Interim Phase II Data of Merck & Co., Inc.'s Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for Study of Liver Diseases Annual Meeting